Ezetimibe and Statins: Evidence-Based Approach to Lowering LDL Cholesterol

Heart disease is the world's biggest killer — and it is only getting worse. [1]

Research continues to confirm that safe, affordable, and highly effective strategies exist for reducing cardiovascular risk. A landmark Swedish population study has reinforced just how powerful early combination therapy can be for lowering LDL cholesterol and protecting heart health over time.

Table of Contents

• The New Study
• Addressing the LDL Cholesterol Debate
• Medications for Lowering LDL-C
• Reference List

The New Study

Researchers set out to question the standard approach to treating heart disease. When someone has experienced a heart attack, clinical guidelines recommend lowering low-density lipoprotein (LDL) cholesterol as aggressively as possible — this is one of the most effective ways to reduce the risk of further heart attacks and cardiovascular complications.

The standard guidelines take a somewhat surprising approach. In addition to diet and exercise, guidelines advise starting patients with high-dose statins, then moving to combination therapy if statins alone do not lower LDL cholesterol sufficiently. Combination therapy simply means adding another medication alongside statins to achieve a stronger effect.

This approach is surprising because research already demonstrates that combination therapy following a heart attack achieves lower LDL cholesterol levels and better outcomes than statins alone — and more than 80% of patients ultimately require combination therapy. [2]

Researchers asked: what would happen if combination therapy were started right away after a heart attack, rather than waiting to see whether statins alone were sufficient? [3]

In other words, if evidence supports combination therapy and most patients end up needing it, could starting it earlier produce meaningfully better outcomes?

The research team examined a large Swedish population of heart attack survivors, dividing them into three groups: those who started combination therapy early, those who started it later, and those who remained on statins alone. Patients were followed for an average of approximately four years, with outcomes measured including further heart attacks and strokes.

The results were striking. Compared to the early combination therapy group, those who started later had a significantly higher risk of death from heart disease. The group that remained on statins alone had an even higher risk. [3]

The conclusion was clear: starting patients on combination therapy early can save lives and deliver substantially better outcomes overall.

Addressing the LDL Cholesterol Debate

This study focused on individuals who had already experienced a heart attack. But there is a much broader lesson relevant to anyone concerned about long-term cardiovascular health. Before exploring that lesson, it is worth addressing a common objection that circulates online whenever LDL cholesterol is discussed.

A popular narrative among certain health commentators holds that "high LDL cholesterol isn't actually a problem — this is a myth created by pharmaceutical companies to sell medications."

Some online sources argue that low cholesterol is the more dangerous condition. Supporters of this view cite studies including graphs showing the relationship between LDL cholesterol and all-cause mortality, with the highest mortality rates appearing at the lowest cholesterol levels. [4]

So what is actually going on? Is there really a conspiracy among doctors and pharmaceutical companies to push unnecessary medications — especially given that both statins and ezetimibe are off-patent and extremely inexpensive?

The first thing to recognise is that this U-shaped pattern appears in many health metrics. A meta-analysis examining BMI in older adults, for instance, produces a strikingly similar chart. [5]

This does not suggest that everyone should aim to be overweight for better health outcomes.

The same pattern appears with blood pressure. [6]

If there were a conspiracy, it would seem to operate across virtually every area of medicine. The actual explanation has nothing to do with deception — it is straightforward epidemiology:

People at the very low end of metrics such as cholesterol, BMI, and blood pressure tend to fall into two categories: older adults and those with chronic illness. In advanced age, many health problems emerge that affect these metrics. BMI, for example, tends to fall in older adults as appetite decreases and weight reduces — while mortality rates simultaneously rise.

Similar reasoning applies to the chronically ill. Very low cholesterol can be caused by liver disease and cancer, which also raise mortality rates. The low cholesterol is a symptom of underlying illness, not a cause of the poor outcomes.

When studies carefully correct for confounders such as old age and chronic illness, the picture changes substantially. One large cohort study of more than 40,000 patients examined overall mortality and initially found high apparent death risk at the lowest non-HDL cholesterol levels.

After adjusting for age, malnutrition, and other markers of poor health, the U-shape disappeared entirely. Higher cholesterol levels were clearly associated with greater mortality risk. [7]

Observational studies carry inherent limitations, which is why the evidence base extends far beyond them. A comprehensive review examining over 200 studies — including randomised controlled trials involving more than two million people — found a consistent pattern: higher LDL cholesterol in the blood correlates with a higher rate of heart disease. [8] The causal evidence was considered strong enough for the study authors to conclude that LDL causes heart disease.

A separate question concerns people who are otherwise entirely healthy. Online commentators sometimes claim that if weight, blood pressure, blood glucose, and insulin sensitivity are all optimal, LDL cholesterol levels are irrelevant.

The PESA study addresses this directly. It found that arterial plaque can develop at LDL-C levels above approximately 50–60 mg/dL — even when all other cardiovascular risk factors are optimal. [9][10]

A more recent study that circulated widely on social media suggested that extremely high LDL cholesterol might be safe in certain individuals on ultra-low-carbohydrate diets — so-called "lean mass hyper-responders." [11] These individuals were otherwise extremely healthy, with sky-high LDL-C levels. As the evidence predicted, they experienced rapid plaque progression in their blood vessels.

For a deeper examination of that research, see the related write-up on this site. The weight of evidence consistently points in one direction: LDL cholesterol is a meaningful, modifiable risk factor for cardiovascular disease — and there are safe, effective strategies for managing it.

Medications for Lowering LDL-C

This brings the discussion back to the core lesson of the Swedish study. Understanding the evidence has practical implications for anyone considering how to approach their long-term cardiovascular health.

First, it is essential to emphasise that regular exercise and a high-quality diet are the foundation of cardiovascular risk reduction. These remain two of the most powerful levers available for modifying risk at a population and individual level.

Specific dietary components can make a meaningful difference. Soluble fibre, for example, has well-documented cholesterol-lowering effects. A Cochrane systematic review confirmed that dietary fibre supplementation reduces cardiovascular disease risk factors. Psyllium husk is among the most studied soluble fibres, and its cholesterol-lowering properties have been demonstrated across multiple clinical trials.

What clinical practice consistently shows, however, is that diet and exercise alone are often insufficient to reach more aggressive LDL cholesterol targets. At that point, low-dose statins are a well-evidenced first-line pharmacological option.

A significant amount of online commentary claims that statins cause dementia. This concern has been disproven in multiple clinical trials. [14] Current clinical guidelines suggest statin use may actually reduce dementia risk. [13]

Statins do not affect testosterone levels. [15] Muscle pain is a relatively uncommon side effect, occurring in approximately 1–2 patients out of 100. [16][17] Those risks are even lower with low-dose therapy, which provides around 70% of the LDL-lowering effect of a high dose at a substantially reduced likelihood of side effects.

For those seeking to push LDL levels lower still, ezetimibe can be added. Ezetimibe is very well tolerated: only a small minority of patients experience mild gastrointestinal effects, and these typically resolve. It was the second medication used in the combination therapy arm of the Swedish study. Its mechanism of action differs from statins — rather than reducing cholesterol synthesis in the liver, ezetimibe reduces how much cholesterol is absorbed through the intestines. Together, the two medications produce a dramatic combined effect.

A recent meta-analysis found that combination therapy lowers cholesterol levels more effectively and is better tolerated than high-dose statin monotherapy. [18] Combining a low- or moderate-dose statin with ezetimibe achieves superior LDL-lowering outcomes with fewer side effects than simply escalating the statin dose.

This is the central lesson of the Swedish study: cardiovascular disease is the result of a cumulative process in which arterial damage accumulates over time. Starting effective therapy early compounds the cardiovascular benefit over a lifetime. In the research, the group that began combination therapy right away experienced the greatest long-term benefits. [3]

There is no need to wait for a first heart attack to begin capturing these cumulative benefits. Starting earlier compounds the protective effect over decades — and the evidence also shows it is never too late to begin. A UK analysis of individuals with no prior heart disease who used statins preventively found that benefits accumulate across a lifetime of use. [12]

When it comes to statin selection, the clinical evidence points toward low-dose hydrophilic statins — specifically pravastatin (20 mg), rosuvastatin (5 mg), or pitavastatin (1–2 mg) — as the preferred starting point when combined with ezetimibe. Hydrophilic statins are water-soluble and do not accumulate in muscle and fat tissue the way lipophilic statins (such as atorvastatin or simvastatin) do. This pharmacokinetic difference is thought to explain why hydrophilic statins tend to have a more favourable muscle-related side effect profile. Pravastatin costs only a few dollars per month in the US at the time of writing. [19] Ezetimibe (10 mg per day) is the standard add-on for combination therapy. [20] Both are off-patent and widely available at very low cost — a combination that makes this approach accessible to a broad population.

The broader principle is compelling: rather than waiting until LDL-C causes a clinical event, addressing it early through a combination of diet, exercise, and — where appropriate — low-dose pharmacological therapy gives the best chance of preventing the slow, cumulative arterial damage that underlies the majority of cardiovascular events.

For anyone considering this approach, a conversation with a qualified healthcare provider is the appropriate next step — they can assess individual cardiovascular risk factors, review current LDL levels, and determine whether pharmacological intervention is warranted and at what dose.

Reference List

1. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death
2. https://www.sciencedirect.com/science/article/pii/S0735109725003596
3. https://www.sciencedirect.com/science/article/pii/S0735109725003596
4. https://www.nature.com/articles/s41598-021-01738-w
5. https://www.sciencedirect.com/science/article/pii/S0002916523050244#f2
6. https://www.sciencedirect.com/science/article/pii/S0735109714029088
7. https://www.sciencedirect.com/science/article/pii/S0261561422000371
8. https://pubmed.ncbi.nlm.nih.gov/28444290/
9. https://www.sciencedirect.com/science/article/pii/S0735109721051159?via%3Dihub
10. https://www.sciencedirect.com/science/article/pii/S0735109721051159?via%3Dihub
11. https://www.jacc.org/doi/10.1016/j.jacadv.2025.101686
12. https://academic.oup.com/eurheartj/article/43/Supplement_2/ehac544.2850/6746257
13. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01296-0/fulltext
14. https://pubmed.ncbi.nlm.nih.gov/25575908/
15. https://www.cochrane.org/CD013211/HTN_what-effect-atorvastatin-testosterone-and-other-hormone-levels-men-and-women
16. https://www.thelancet.com/article/S0140-6736(22)01545-8/fulltext
17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613583/
18. https://pubmed.ncbi.nlm.nih.gov/39135464/
19. https://www.costplusdrugs.com/medications/pravastatin-20mg-tablet/
20. https://www.costplusdrugs.com/medications/ezetimibe-10mg-tablet/